Durcy Verenice Ruiz Ciau

Dr. Durcy Verenice Ruiz Ciau


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 May 2022 in Scientia Pharmaceutica
Verified
Journal Article
Open access
PDF file
CSCarla Georgina Cicero Sarmiento
Carla Georgina Cicero Sarmiento
RORolffy Ortiz-Andrade
Rolffy Ortiz-Andrade
Jesús Alfredo Araujo-LeónJesús Alfredo Araujo-León
Jesús Alfredo Araujo-León
MCMaira Segura Campos
Maira Segura Campos
PGPriscila Vazquez Garcia
Priscila Vazquez Garcia
DCDurcy Verenice Ruiz Ciau
Durcy Verenice Ruiz Ciau
We developed a naringenin–hesperidin molar mixture (MIX–160) with proven antihyperglycemic and vasorelaxant activity in preclinical studies. A solid dosage form was manufactured to improve the bioavailability properties. In the current study, we sought to evaluate the oral preclinical toxicity of the MIX–160 dosage form, which showed no mortality or significant changes in the body weight, food consumption and tissue/organ mass in rats. Three daily oral doses (50, 300 and 2000 mg/kg of MIX–160) were assayed for 28 days. The results showed no structural abnormalities in the histological analysis and no significant changes (p > 0.05) in the liver biochemical markers (total bilirubin, AST and ALT) compared to the control group. The above findings showed that the MIX–160 dosage form did not exhibit relevant toxic effects, which suggests its potential safety as a drug candidate for clinical studies.